News Center
What new measures does the group have in the Year of the Sheep? The top-level "flower voice" tells you.
Release time:
2015-02-27
What new measures does the group have in the Year of the Sheep? The top-level "flower voice" tells you.
On the first day of the New Year, Mr. Tao Desheng, the president of the Lijuzhu Group, convened a meeting of the company's senior and middle managers to deploy the annual work and set clear goals.He formulated feasible measures. More than 150 members of the board, senior management, and managers attended.The meeting was hosted by Assistant President Zhou Peng.
President Tao Desheng deployed the group's comprehensive work, pointing out that prioritizing quality and safety in production is essential; the significant investment in R&D is a necessary requirement for maintaining healthy and sustainable development; the market environment for sales is under severe pressure.Efforts are being made to grow stronger; the annual target plan for the raw materials pharmaceutical division is encouraging, and it is hoped that it can be achieved. The company has already set clear goals and responsibilities in all aspects. In summary: streamline administration and delegate power to optimize.Strengthen crisis management. Ultimately, it still relies on people.It relies on the team!
Yang Daihong, Vice President of Production Technology, illustrated through a humorous story: Safety in production requires constant vigilance; quality comes first, with strict control; cost control serves the market, and the headquarters relocation will be completed within the year.
Lu Wenqi, Vice President of R&D, stated: The group's R&D work must face challenges head-on and build a team; utilize platforms to select quality products.
Dr. Fu Daotian, Vice President of the Group and General Manager of the Monoclonal Antibody Company, said: The monoclonal antibody and vaccine companies are determined to establish themselves in Lijuzhu and prosper in the Year of the Goat; build a solid team and create new platforms.
Si Yanxia, Vice President of the Group and head of finance, expressed her views on financial and information work: Provide support for equity incentives, focus on the quality and efficiency of fund usage; ensure timely and accurate resource allocation for sales, and optimize and stabilize the IT platform for the company.
Tang Yanggang, General Manager of the Group's Raw Materials Pharmaceutical Division, actively offered suggestions regarding his responsibilities: Now, the goals in the field of raw materials pharmaceuticals are clear, and the measures are defined; we must seize opportunities to achieve steady growth in the recovering market.
Li Rucai, Assistant President of the Group and head of investment and securities, stated regarding his responsibilities: We must actively carry out the follow-up work of equity incentives, allowing key employees to share in the dividends of the company's development; at the same time, we must handle capital mergers and acquisitions to expand the company's scale.
Related Information